Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport

被引:83
作者
Sakaeda, T
Fujino, H
Komoto, C
Kakumoto, M
Jin, JS
Iwaki, K
Nishiguchi, K
Nakamura, T
Okamura, N
Okumura, K
机构
[1] Kobe Univ, Sch Med, Dept Hosp Pharm, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Kowa Co Ltd, Tokyo New Drug Res Labs 1, Higashimurayama 1890022, Japan
[3] Kobe Univ, Grad Sch Med, Dept Clin Evaluat Pharmacotherapy, Kobe, Hyogo 6500047, Japan
关键词
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins); CYP; drug-drug interaction; MDR1;
D O I
10.1007/s11095-005-9371-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. With the growing clinical usage of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), the number of reports concerning serious drug-drug interaction has been increasing. Because recent studies have shown that conversion between acid and lactone forms occurs in the body, drug-drug interaction should be considered on both acid and lactone forms. Thus, we investigated the inhibitory effects of acid and lactone forms of eight statins. including one recently withdrawn, cerivastatin, and two recently developed, pitavastatin and rosuvastatin, on cytochrome P450 (CYP) 2C8, CYP2C9, and CYP3A4/5 metabolic activities and multidrug, resistance protein 1 (MDR1) transporting activity. Methods. The inhibitory effects of statins on CYP metabolic activities and MDR1 transporting activity were investigated using human liver microsomes and MDR1-overexpressing LLC-GA5-COL150 cells. respectively. Results. The acid forms had minimal inhibitory effects on all CYP activities tested, except for fluvastatin on CYP2C9-mediated tolbutamide 4-hydroxylation (IC50 = 1.7 mu M) and simvastatin on CYP3A4/5-mediated paclitaxel 3-hydroxylation (12.0 mu M). Lactone forms showed no or minimal inhibitory effects on CYP2C8. CYP2C9, and CYP2C19 activities, except for rosuvastatin on the CYP2C9 activity (20.5 mu M), whereas they showed stronger inhibitory effects on the CYP3A4/5 activity with the rank order of atorvastatin (5.6 mu M), cerivastatin (8.1 mu M), fluvastatin (14.9 mu M), simvastatin (15.2 mu M), rosuvastatin (20.7 mu M), and lovastatin (24.1 mu M). Pitavastatin and pravastatin had little inhibitory effect, and a similar order was found also for testosterone 6 beta-hydroxylation. MDR1-mediated transport of [H-3]digoxin was inhibited only by lactone forms, and the rank order correlated with that of inhibitory effects on both CYP3A4/5 activities. Inhibitory effects on MDR1 activity, and on both CYP3A4/5 activities, could be explained by the lipophilicity; however. a significant cot-relation was found between the lipophilicity and inhibitory effects on CYP2C8-mediated paclitaxel 6 alpha-hydroxylation. Conclusions. We showed the difference between the acid and lactone forms in terms of drug interaction. The lipophilicity Could be one of the important factors for inhibitory effects. In the case of statins, it is important to examine the effects of both forms to understand the events found in clinical settings, including the pleiotropic effects.
引用
收藏
页码:506 / 512
页数:7
相关论文
共 48 条
  • [1] Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin
    Ando, H
    Tsuruoka, S
    Yanagihara, H
    Sugimoto, K
    Miyata, M
    Yamazoe, Y
    Takamura, T
    Kaneko, S
    Fujimura, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (05) : 494 - 497
  • [2] Oral anticoagulant drug interactions with statins: Case report of fluvastatin and review of the literature
    Andrus, MR
    [J]. PHARMACOTHERAPY, 2004, 24 (02): : 285 - 290
  • [3] Gemfibrozil greatly increases plasma concentrations of cerivastatin
    Backman, JT
    Kyrklund, C
    Neuvonen, M
    Neuvonen, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) : 685 - 691
  • [4] Rosuvastatin-warfarin drug interaction
    Barry, M
    [J]. LANCET, 2004, 363 (9405) : 328 - 328
  • [5] Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
    Benet, LZ
    Cummins, CL
    Wu, CY
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 277 (1-2) : 3 - 9
  • [6] Transporter-enzyme interactions:: Implications for predicting drug-drug interactions from in vitro data
    Benet, LZ
    Cummins, CL
    Wu, CY
    [J]. CURRENT DRUG METABOLISM, 2003, 4 (05) : 393 - 398
  • [7] The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, SR
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05) : 443 - 469
  • [8] INTERNAL DUPLICATION AND HOMOLOGY WITH BACTERIAL TRANSPORT PROTEINS IN THE MDR1 (P-GLYCOPROTEIN) GENE FROM MULTIDRUG-RESISTANT HUMAN-CELLS
    CHEN, CJ
    CHIN, JE
    UEDA, K
    CLARK, DP
    PASTAN, I
    GOTTESMAN, MM
    RONINSON, IB
    [J]. CELL, 1986, 47 (03) : 381 - 389
  • [9] Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
    Fujino, H
    Saito, T
    Tsunenari, Y
    Kojima, J
    Sakaeda, T
    [J]. XENOBIOTICA, 2004, 34 (11-12) : 961 - 971
  • [10] Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization
    Fujino, H
    Yamada, I
    Shimada, S
    Yoneda, M
    Kojima, J
    [J]. XENOBIOTICA, 2003, 33 (01) : 27 - 41